Streptococcus suis serotype 2 is an emerging zoonotic pathogen and causes severe 22 disease in both pigs and human beings. Cefquinome (CEQ), a fourth-generation 23 cephalosporin, exhibits a broad spectrum activity against Gram-positive bacteria such 24 as S. suis. This study evaluated the in vitro and in vivo antimicrobial activities of CEQ 25 against four strains of S. suis serotype 2 in a murine neutropenic thigh infection model. 
Matrix-matched calibration standards gave linear responses from 0.001 to 1µg/mL (r 155 ＞0.995) and both the intra-day and inter-day variations were less than 7.3%. A value 156 of 92.6% CEQ protein binding was obtained from a previous report and used to 157 calculate serum-free drug concentrations (10). 158
159
In vivo post-antibiotic effects. S. suis II strain ATCC 43765 was used to produce 160 thigh infection mice for determining PAE. Infection mice were injected s.c. with 0.2 161 mL single doses of CEQ at 2.5 and 40 mg/kg at 2 h post-infection. Untreated control 162 growth was determined at seven sampling times (two mice per time point) over 24 h 163 with sampling at 0, 2, 4, 6, 8, 12 and 24 h. The treated groups (two mice per time 164 point) were sampled nine times over 24h at 1, 2, 3, 4, 6, 8, 12, and 24 h. The PAE was 165 calculated by subtracting the time it took the pathogens to increase 1 log in the thighson January 14, 2018 by guest http://aac.asm.org/ Downloaded from of untreated control animals from the time it took the pathogens to increase the same 167 amount in treated animals after serum drug levels decreased below the MIC of the 168 drug for the pathogens(22). The equation for calculating the PAE was as follows: 169 PAE=T-C, where T is the time for the growth of 1-log 10 in treated animals after the 170 free-drug levels in serum had fallen below the MIC. C is the time for the growth of 171 1-log 10 in untreated control animals (23). 172 173 PK-PD index determination. In vivo activity was determined for mice with systemic 174 infection of standard S. suisⅡ ATCC 43765 using two inoculum sizes. The therapy 175 started at 2 h post-infection and 28 dosing regimens were used to determine the 176 effects of dosing level and interval on CEQ efficacy. These regimens consisted of 6 177 dosage levels at a 4-fold-incremental (0.625 to 640mg/kg/24 h) and consisted of 4 178 dosing intervals at 24, 12, 6, and 3 hrs (i.e., 1, 2, 4 or 8 doses every 24 hrs). Groups of 179 two mice were involved in each dosing regimen. The mice were euthanized after 24 h 180 and each thigh was immediately removed and processed for CFU determination. The 181 untreated control mice were sacrificed just before CEQ administration and after 24 h. 182 183 PK-PD parameter magnitude studies. Similar to the experiments described above, 184 mice were infected with three additional strains of S. suisⅡ (GD110, GF114 and 185 GD4).The mice were then treated with CEQ doses administered every 6 h for 24 h 186 and varied from 0.625 to 160 mg/kg and from 0.625 to 640 mg/kg for the SI and HI 187 groups, respectively. Two mice were used for each dosing regimen. At the end of 188 study, the mice were euthanized and each thigh was removed and processed as 189 equal to the log change in CFU per thigh between treated and untreated controls mice 204 after the 24-h period of the study; E max is maximum effect; C is the PK-PD parameter 205 being examined (% ƒT＞ MIC ƒC max / MIC, and ƒAUC / MIC) as well as the 24-h total 206 dose in this study; EC 50 is the C value that results in 50% of the E max ; and N is a 207 sigmoid factor that controls the slope of the curve. Nonlinear regression analysis was 208 used to determine which PK-PD index best correlated with the CFU/thigh at 24 h at 209 two inoculum sizes. The coefficients of determination (R 2 ) were used to estimate the 210 variance associated with regression modeling with each of the PK-PD indices. Doses 211 calculated by the sigmoid E max model for the static and 1-log kill at different inocula 212 and the rate of dose between SI and HI (IE index) were compared by t tests. 213
214

RESULTS
215
In vitro susceptibility testing and time-kill curves. The MICs of CEQ against the 216 studied strains at two inoculum sizes are listed in Table 1 and ranged from 0.03 to 217 0.24 µg/mL. We initiated this study by evaluating the effects of inoculum size on MIC 218 determination. The higher inoculum size resulted in MICs that were only 2-to 4-fold 219 higher than those at SI and ranged from 0.06 to 0.5 µg/mL (Table 1) . These results 220
were not judged as significant (P=0.25). Additionally, The MICs of the pre-and 221 post-treatment isolates at SI and HI exposed to CEQ therapy in the thighs of treated 222 on January 14, 2018 by guest http://aac.asm.org/ Downloaded from mice were monitored. However, the value of MIC of those organisms have not been 223 changed, indicating that pre-existing and/or occurring mutant isolations did not 224 happened during the experiment. 225
We next evaluated the time-dependent killing action of CEQ against S. suisⅡ 226 ATCC 43765. The organism grew under control conditions with a mean of 2.6 ± 0.16 227 (SI) and 0.86 ± 0.09 (HI) log 10 CFU/mL after 12 h. The onset rate of killing between 228 the two inoculum sizes was similar during the first 6 hours. After this period, 2×MIC 229 yielded a bacteriostatic activity for SI and 4×MIC achieved a maximal killing, with 230 higher concentration providing little added benefit (Fig. 1) . However, in the HI group, 231 the CEQ bactericidal activity was markedly attenuated and even increasing the 232 concentration to 32× MIC could not achieved bactericidal activity (Fig. 1) . 233 Escalating doses of CEQ resulted in the time-dependent killing of both inocula. For 264 the SI group the changes in log CFU had the strongest correlation with %ƒT＞MIC 265 (R 2 = 91%). Correlation with ƒAUC/MIC (R 2 = 58%) and the ƒC max /MIC ratio (R 2 = 266 37%) were both poor (Fig. 4) . 267
At the higher inoculums, %ƒT＞MIC value still held the best correlation (R 2 = 268 63%) although the non-linear curve was shifted somewhat to the top indicating a 269 diminished effect at the bactericidal efficacy. As with the SI group, there was no 270 correlation between log CFU and the other indices (Fig. 4) .These data demonstrated 271 that %ƒT＞MIC was the most closely linked to the treatment efficacy at both SI and 272 HI even though HI reduced the value of the %ƒT＞MIC. 273
274
Magnitudes of %ƒT＞ MIC and doses required for efficacy. To determine whether the 275 lengths of exposure and the amount of doses required for efficacy were similar for the 276 various inocula, the antibiotic activities of the CEQ 6 h dosing regimens against 3 277 additional strains of S. suisⅡ were performed. At the start of therapy, mice had 278 on January 14, 2018 by guest http://aac.asm.org/ Downloaded from 6.16±0.26 and 8.12 ±0.22 log 10 CFU/thigh with a growth rate of 1.22±0.14 and 0.34 279 ±0.12 log 10 CFU/thigh after 24 h in untreated control mice at SI and HI, respectively. 280
The degree of exposure (%ƒT＞MIC) necessary to achieve a net static and 1-log 10 kill 281 against multiple organisms are listed in Table 3 . The %ƒT＞MIC were not statistically 282 different in the degree of CEQ exposure required to achieve a net bacteriostatic effect 283 between SI and HI (P=0.19). There was, however, roughly a 2-fold increase in the 284 1-log killing for the HI group (P=0.01). 285
The CEQ dosages required for stasis and 1-log killing are shown in Table 4 . 286
The IE index for the stasis effect was low (1.59±0.67) and for the 1-log kill increased 287 to 4.47±1.21. HI showed a statistically significant effect on the magnitude of dosage 288 required for 1-log kill efficacy and were almost 4-fold higher than those for the SI 289 S.suis is considered as the paradigm for the intersections between animal and 298 human resistomes [23] . Therefore, the prudent use of β-lactams for S. suisⅡinfections 299 in pigs is essential to maintain the therapeutic efficacy and to minimize selection of 300 resistant S. suis strains. 301 CEQ was chosen in this study due to its broad antibacterial spectrum and that it 302 represents a reliable a choice for the initial empirical treatment in the case of a critical 303 illness. We used PK/PD modeling as a scientific tool in an attempt to establish optimal 304 dosing regimens and provide guidelines for empirical therapy. To the best of our 305 knowledge, the current study is the first to evaluate the in vivo pharmacodynamic 306 on January 14, 2018 by guest http://aac.asm.org/ Downloaded from activity of CEQ against S. suis II. The PK/PD analysis determined that: (ⅰ) CEQ 307 produced a significant and prolonged PAE (ⅱ) the variable %ƒT＞MIC was most 308 closely linked to efficacy with both inoculum sizes although this was most effective at 309 the lower standard dose and ( ⅲ ) the in vitro time-kill study linked in vivo 310 experiments demonstrated that efficacy of CEQ was weaken with increasing bacterial 311 density. 312 PAE have been demonstrated with CEQ against S. suis II since the persistent 313 suppression of bacterial regrowth was observed. Meanwhile, We can notice that the 314 regrowth was not happened immediately after the drug levels had decreased below the 315 MIC, which was probably due to a post-antibiotic sub-inhibitory concentrations 316 ( PA-SME )(25). In the in vivo situation, a supra-inhibitory concentration of a drug 317 would always be followed by sub-inhibitory concentrations (sub-MICs). Persisting 318 sub-MICs remained at the thighs of infection mice was difficult to separate from true 319 in vivo PAE in an animal model, resulting in an increase in the in vivo PAE(26). The 320 presence of prolonged PAEs would prevent the bacterial regrowth immediately 321 between the doses, and then, allow more widely spaced dosing intervals without loss 322 of efficacy(27). CEQ induced a prolonged PAE that ranged from 2.45 to 8.55 h and 323 was directly correlated with dose. This phenomenon was similar to the long PAE 324 times of β-lactams used against Staphylococcus spp(28). However, this data conflicts 325 with earlier studies that found nonexistent or short PAEs for β-lactams against S. 326 pneumoniae in vivo (29). This difference may be due to differences in growth rates 327 between S. suis and S. pneumoniae. S. pneumoniae multiplies too slowly in vivo to 328 reach the time required for a 1-log 10 increase. 329
Using the standard inoculums, the mean value of %ƒT＞MIC required for 330 stasis and 1-log kill against the four strains of S. suis II were 20.74% and 37.06 %, 331 respectively. These data were similar to the %ƒT＞MIC requirement for the antibiotic 332 activities of other cephalosporins against Staphylococcus spp, however, they were 333 lower than those against S. pneumoniae (28). evaluated cefepime against E. coli using TEM-derived ESBLs and found that no 366 differences in exposure times and static doses were required for efficacy using varying 367 inoculum sizes (34). Lee et al reached the same conclusions with their work using S. 368 pneumoniae (32). However, in that same study, opposite results were observed for 369
MRSA. There was a reduction in killing effect with vancomycin and ceftobiprole 370 using large inoculum sizes. Furthermore, two other studies that reported IE exerts a 371 significant influence suggested that higher β-lactam doses would be necessary for 372 efficacy when dense bacterial infections were encountered (15) (19). Our results are in 373 agreement with the latter study. 374
Using dose fractionation experiments, the %ƒT＞MIC value was associated with 375 efficacy and the HI group showed a lower correlation than SI. In the HI infection 376 model, there was a significant relationship between efficacy and %ƒT＞MIC in the 377 0-40 range (%ƒT＞MIC). However, achieving bactericidal activities were not only 378 correlated to %ƒT＞MIC but also the drug concentration. When this was extended to 379 3 additional strains, we again observed that higher doses (4-fold) and longer exposure 380 times (%ƒT＞MIC) were necessary for a 1-log kill. 
